Cancer Q1 Unclaimed

John Wiley and Sons Inc. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 304. Journal with a Single blind Peer Review review system, and It has a price of 2500 €. The scope of the journal is focused on Cancer, Medicine, Oncology, Cancer statistics, Cancer Diagnosis. It has an SJR impact factor of 3,052 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 3,052.

Cancer focuses its scope in these topics and keywords: cancer, patients, cell, squamous, carcinoma, breast, care, human, study, prostate, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

2500 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Cancer

3,052

SJR Impact factor

304

H Index

727

Total Docs (Last Year)

1858

Total Docs (3 years)

21672

Total Refs

9435

Total Cites (3 years)

1382

Citable Docs (3 years)

4,63

Cites/Doc (2 years)

29,81

Ref/Doc

Aims and Scope


cancer, patients, cell, squamous, carcinoma, breast, care, human, study, prostate, lung, clinical, cancerthe, intraepithelial, stage, effects, survival, therapy, treatment, screening, pancreatic, multiple, Cancer, Medicine, Oncology, Cancer statistics, Cancer Diagnosis



Best articles by citations

Locally advanced breast cancer

View more

Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy

View more

RefractoryAspergillus pneumonia in patients with acute leukemia

View more

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma

View more

Oncofertility and preservation of reproductive capacity in children and young adults

View more

Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma - Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group

View more

Increasing the pool of academically oriented African-American medical and surgical oncologists

View more

Cell-mediated immunity to varicella zoster virus in children being treated for cancer

View more

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha

View more

Changes in standardized mortality rates from thyroid cancer in Korea between 1985 and 2015: Analysis of Korean national data

View more

Adenosquamous carcinoma of the pancreas

View more

Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies

View more
SHOW MORE ARTICLES

Detection, treatment, and outcome of isolated supraclavicular recurrence in 42 patients with invasive breast carcinoma

View more

Message from the editor

View more

Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-hodgkin lymphoma

View more

Intensity of immunosuppressive therapy and the incidence of pneumocystis carinii pneumonitis

View more

Hospitalization of an oncology patient suspected of having severe acute respiratory syndrome

View more

The value of routine follow-up in patients treated for carcinoma of the vulva

View more

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease

View more

Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group

View more

Advance directives in the intensive care unit of a tertiary cancer center

View more

Touch imprint cytology of axillary lymph nodes after neoadjuvant chemotherapy in patients with breast carcinoma

View more

Author reply

View more

Mycotic infections in leukemic patients at autopsy

View more

Comments

No comments ... Be the first to comment!

FAQS